AbCellera Biologics (ABCL) said Health Canada authorized its clinical trial application for a phase 1 study of an investigational antibody medicine designed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, known as hot flashes, associated with menopause.
The trial for ABCL635 is expected to begin in Q3 and will evaluate the treatment's safety profile, pharmacokinetics and pharmacodynamics in healthy participants and postmenopausal women with symptoms, the Vancouver-based company said Wednesday in a statement.
The company's shares rose 0.1% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。